B
Bull
Bull · 25%WINT
$1.46
情景价格
$0.110
-0.085 (-77.21%)收盘时
Loading chart…
- High
- 0.496
- Open
- 0.480
- VWAP
- 0.24
- Vol
- 56.03M
- Mkt Cap
- 1.95M
- Low
- 0.100
- Amount
- 13.18M
- EV/EBITDA, TTM
- 0.00
Windtree Therapeutics, Inc. is a diversified company. The Company is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The Company also has a licensing business model with partnership out-licenses in place. The Company is also focused on environmental services space.
估值指标
The current forward P/E ratio for Windtree Therapeutics Inc (WINT) is -0.01, compared to its 5-year average forward P/E of -1.07.
Alphio AI Price Scenarios for WINT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
8.512-03NewsfilterWindtree Acquires CommLoan to Expand Fintech Operations
- 9.008-05Newsfilter
Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients
- 8.507-29Newsfilter
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
4.507-25BenzingaWhy Are Public Companies Ammassing ETH, XRP, SOL, BNB Instead Of Just Bitcoin?
2.007-17BenzingaDow Jumps Over 100 Points; PepsiCo Posts Upbeat Earnings
WINT FAQ — answered by Alphio AI
Windtree Therapeutics, Inc. is a diversified company. The Company is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The Company also has a licensing business model with partnership out-licenses in place. The Company is also focused on environmental services space. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。